[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559720":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":43,"centralContacts":47,"locations":55,"responsibleParty":57,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":55,"enrollmentInfo":72,"targetDuration":55,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":55,"overallStatus":81,"whyStopped":55,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":55},{"fullName":5,"class":6},"Hamilton Health Sciences Corporation","OTHER",[8,14,18,23],{"label":9,"type":10,"description":11,"interventionNames":12},"cefazolin short-term","EXPERIMENTAL","Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first).",[13],"Drug: Cefazolin",{"label":15,"type":10,"description":16,"interventionNames":17},"cefazolin long-term","Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first) and the five post-operative doses in the long-term arms will be 2g every 8 hours.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"cefazolin plus vancomycin short-term","Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first). Vancomycin will be dosed at roughly 15mg\u002Fkg body weight intravenously, i.e. 1g or 1.5g if greater than 85kg body weight and is to be administered within 60-90 minutes of the surgical procedure.",[13,22],"Drug: Vancomycin",{"label":24,"type":10,"description":25,"interventionNames":26},"cefazolin plus vancomycin long-term","Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first) and the five post-operative doses in the long-term arms will be 2g every 8 hours. Vancomycin will be dosed at roughly 15mg\u002Fkg body weight intravenously, i.e. 1g or 1.5g if greater than 85kg body weight and is to be administered within 60-90 minutes of the surgical procedure. The same dose will be used for the 3 post-operative doses in the long-term arm.",[13,22],[28,36],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","Cefazolin","administration as outlined",[15,24,19,9],[34,35],"Kefzol","Ancef",{"type":29,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Vancomycin","administered as outlined",[24,19],[41,42],"Vancocin","Firvanq",[44],{"name":45,"affiliation":5,"role":46},"Dominik Mertz, MD, MSc","PRINCIPAL_INVESTIGATOR",[48,53],{"name":45,"role":49,"phone":50,"phoneExt":51,"email":52},"CONTACT","905-521-2100","43952","mertz@hhsc.ca",{"name":54,"role":49,"phone":55,"phoneExt":55,"email":56},"Ingrid Copland",null,"pics@phri.ca",{"type":58,"investigatorFullName":55,"investigatorTitle":55,"investigatorAffiliation":55,"oldNameTitle":55,"oldOrganization":55},"SPONSOR",[60],{"name":61,"class":62},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV","100559720","phase-4-prevention-of-infections-in-cardiac-surgery-pics-a-cluster-randomized-factorial-cross-over-trial-100559720",false,"NCT06567808","Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial","PICS","Inclusion Criteria:\n\nAdult patients (≥18 years of age) undergoing open-heart surgery (i.e. sternotomy, including minimally-invasive surgical techniques through mini-sternotomies)\n\nExclusion Criteria:\n\n1. On systemic antibiotics or with an active bacterial infection at the time of surgery\n2. Previously enrolled in this trial\n3. Known to be colonized with methicillin-resistant staphylococcus aureus (MRSA). Where it is unethical to not administer glycopeptides.\n4. Beta-lactam or vancomycin allergy precluding the use of cefazolin or vancomycin, respectively\n5. Participation in other studies that may interfere with this trial.\n6. Patients undergoing cardiac transplant","ALL","18 Years",{"count":73,"type":74},38000,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","The goal of this pragmatic, multi-centre factorial cluster randomized cross-over trial is to assess the efficacy of a combination of cefazolin plus vancomycin compared to cefazolin monotherapy, as well as a comparison of short versus long-term prophylaxis with four study arms: 1) cefazolin short-term, 2) cefazolin long-term, 3) cefazolin plus vancomycin short-term and 4) cefazolin plus vancomycin long-term.",[80],"Infection, Surgical Site","NOT_YET_RECRUITING","2026-03-10",{"date":84,"type":85},"2026-03-12","ACTUAL",{"date":87,"type":74},"2026-03-01",{"date":89,"type":74},"2028-07-30",{"name":5,"class":6}]